Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

BACKGROUND: Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1 agent now FDA-approved in a wide variety of tumor types, and with others in cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Dylan J., Lalani, Aly-Khan A., Bossé, Dominick, Steinharter, John A., Harshman, Lauren C., Hodi, F. Stephen, Ott, Patrick A., Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557522/
https://www.ncbi.nlm.nih.gov/pubmed/28807048
http://dx.doi.org/10.1186/s40425-017-0273-y

Ejemplares similares

Ejemplares similares